MetLife Investment Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $316K | Buy |
55,337
+6,440
| +13% | +$29.2K | ﹤0.01% | 2176 |
|
|
2026
Q1 | $220K | Buy |
48,897
+5,962
| +14% | +$31.1K | ﹤0.01% | 2178 |
|
|
2025
Q4 | $264K | Sell |
42,935
-10,339
| -19% | -$75K | ﹤0.01% | 2139 |
|
|
2025
Q3 | $385K | Sell |
53,274
-505
| -0.9% | -$3K | ﹤0.01% | 1935 |
|
|
2025
Q2 | $286K | Sell |
53,779
-602
| -1% | -$3.56K | ﹤0.01% | 1987 |
|
|
2025
Q1 | $482K | Sell |
54,381
-550
| -1% | -$6.61K | ﹤0.01% | 1746 |
|
|
2024
Q4 | $753K | Buy |
54,931
+3,231
| +6% | +$59.6K | ﹤0.01% | 1568 |
|
|
2024
Q3 | $1.42M | Hold |
51,700
| – | – | 0.01% | 1199 |
|
|
2024
Q2 | $1.26M | Buy |
51,700
+7,693
| +17% | +$169K | 0.01% | 1225 |
|
|
2024
Q1 | $938K | Buy |
44,007
+1,338
| +3% | +$28.8K | 0.01% | 1333 |
|
|
2023
Q4 | $817K | Hold |
42,669
| – | – | 0.01% | 1418 |
|
|
2023
Q3 | $684K | Hold |
42,669
| – | – | 0.01% | 1445 |
|
|
2023
Q2 | $989K | Hold |
42,669
| – | – | 0.01% | 1277 |
|
|
2023
Q1 | $991K | Hold |
42,669
| – | – | 0.01% | 1227 |
|
|
2022
Q4 | $619K | Hold |
42,669
| – | – | ﹤0.01% | 1504 |
|
|
2022
Q3 | $814K | Hold |
42,669
| – | – | 0.01% | 1297 |
|
|
2022
Q2 | $775K | Hold |
42,669
| – | – | 0.01% | 1355 |
|
|
2022
Q1 | $1.08M | Buy |
42,669
+15,255
| +56% | +$390K | 0.01% | 1285 |
|
|
2021
Q4 | $757K | Hold |
27,414
| – | – | 0.01% | 1261 |
|
|
2021
Q3 | $885K | Hold |
27,414
| – | – | 0.01% | 1186 |
|
|
2021
Q2 | $838K | Hold |
27,414
| – | – | 0.01% | 1270 |
|
|
2021
Q1 | $835K | Sell |
27,414
-4,400
| -14% | -$125K | 0.01% | 1247 |
|
|
2020
Q4 | $629K | Hold |
31,814
| – | – | 0.01% | 1364 |
|
|
2020
Q3 | $415K | Hold |
31,814
| – | – | ﹤0.01% | 1465 |
|
|
2020
Q2 | $361K | Hold |
31,814
| – | – | ﹤0.01% | 1556 |
|
|
2020
Q1 | $455K | Hold |
31,814
| – | – | 0.01% | 1266 |
|
|
2019
Q4 | $866K | Hold |
31,814
| – | – | 0.01% | 1163 |
|
|
2019
Q3 | $911K | Hold |
31,814
| – | – | 0.01% | 1117 |
|
|
2019
Q2 | $884K | Sell |
31,814
-57,475
| -64% | -$1.62M | 0.01% | 1165 |
|
|
2019
Q1 | $2.96M | Buy |
89,289
+59,526
| +200% | +$1.81M | 0.01% | 1069 |
|
|
2018
Q4 | $865K | Hold |
29,763
| – | – | 0.01% | 1083 |
|
|
2018
Q3 | $1.37M | Hold |
29,763
| – | – | 0.01% | 1000 |
|
|
2018
Q2 | $1.11M | Hold |
29,763
| – | – | 0.01% | 978 |
|
|
2018
Q1 | $879K | Hold |
29,763
| – | – | 0.01% | 1060 |
|
|
2017
Q4 | $1.02M | Buy |
+29,763
| New | +$1M | 0.01% | 1025 |
|
Other funds holding MYGN
VPC
MetLife Investment Management's MYGN Position: Q2 2026 in Review
MetLife Investment Management increased its Myriad Genetics (MYGN) stake by 13% in Q2 2026, buying an estimated $29.2K and bringing the position to 55,337 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.
MetLife Investment Management first reported a position in MYGN in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.96M in Q1 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- MetLife Investment Management held 55,337 shares of Myriad Genetics worth $316K as of Q2 2026.
- MetLife Investment Management bought 6,440 Myriad Genetics shares in Q2 2026, an estimated $29.2K.
- Myriad Genetics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2176 holding.
- MetLife Investment Management first reported a position in Myriad Genetics in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Myriad Genetics position peaked at $2.96M in Q1 2019.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.